Study design
DISEASE PROGRESSION
The design of the MEDALIST study has been described previously [Patients were randomized 2:1 to receive either luspatercept 1.0 mg/kg subcutaneously or placebo every 3 weeks (Fig. MEDALIST study design. Regardless of meeting the primary endpoint at week 25, patients who had shown clinical benefit (as assessed by the investigators) without disease progression (according to International Working Group (IWG)-MDS criteria) [